A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 1,945 shares of PRTA stock, worth $34,018. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,945
Previous 1,605 21.18%
Holding current value
$34,018
Previous $33,000 3.03%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$16.73 - $24.79 $5,688 - $8,428
340 Added 21.18%
1,945 $32,000
Q2 2024

Jul 30, 2024

SELL
$19.54 - $26.15 $514,038 - $687,928
-26,307 Reduced 94.25%
1,605 $33,000
Q1 2024

May 01, 2024

BUY
$24.75 - $40.66 $3,984 - $6,546
161 Added 0.58%
27,912 $691,000
Q4 2023

Jan 24, 2024

BUY
$32.31 - $52.32 $67,818 - $109,819
2,099 Added 8.18%
27,751 $1.01 Million
Q3 2023

Oct 26, 2023

BUY
$47.3 - $70.6 $152,400 - $227,473
3,222 Added 14.36%
25,652 $1.24 Million
Q2 2023

Aug 10, 2023

SELL
$48.26 - $78.59 $66,984 - $109,082
-1,388 Reduced 5.83%
22,430 $1.53 Million
Q1 2023

May 04, 2023

BUY
$46.97 - $58.27 $334,144 - $414,532
7,114 Added 42.59%
23,818 $1.15 Million
Q4 2022

Feb 09, 2023

BUY
$52.05 - $65.0 $2,758 - $3,445
53 Added 0.32%
16,704 $1.01 Million
Q3 2022

Nov 10, 2022

BUY
$25.16 - $60.63 $144,946 - $349,289
5,761 Added 52.9%
16,651 $1.01 Million
Q2 2022

Jul 26, 2022

BUY
$22.73 - $39.98 $231,209 - $406,676
10,172 Added 1416.71%
10,890 $296,000
Q2 2021

Aug 11, 2021

BUY
$21.63 - $57.65 $15,530 - $41,392
718 New
718 $37,000
Q4 2017

Feb 12, 2018

SELL
$35.44 - $63.76 $117,341 - $211,109
-3,311 Closed
0 $0
Q3 2017

Nov 08, 2017

BUY
$53.83 - $67.75 $178,231 - $224,320
3,311
3,311 $214,000

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $821M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Mirae Asset Global Investments Co., Ltd. Portfolio

Follow Mirae Asset Global Investments Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.